A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Myelodysplastic Syndromes (MDS) · Beta-thalassemia · Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 665 (planned)
- Started
- Aug 12, 2019
- Main results expected
- May 12, 2028
- Fully finished
- May 12, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Adverse Events (AEs)
Measured over: From enrollment until at least 42 Day Safety Follow-up Phase
Number of participants progressing to high/very high risk MDS or AML.
Measured over: Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)
Percentage of participants progressing to high/very high risk MDS or AML
Measured over: Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)
Number of participants developing other malignancies/pre-malignancies
Measured over: Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)
Percentage of participants developing other malignancies/pre-malignancies
Measured over: Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04064060 · record last updated 2026-07-01 · checked 2026-11-09 15:47 UTC